Business Wire

Agendia to Provide First Digital MammaPrint Capability to Brazil

Share

Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced that it is offering early access to its Digital MammaPrint platform for patients with breast cancer in Brazil, expanding the company’s offerings in the country with the goal of bringing essential information from cancer testing to the larger global breast cancer community. Brazil is the first country to have samples analyzed by Digital MammaPrint, allowing physicians and their patients to benefit from genomic insights derived from a digitized image of a breast cancer tumor. Results about individual tumors will now be informed by the new artificial intelligence (AI) platform, also providing better turnaround time for their treatment decisions.

By offering Brazilian physicians and their patients early access to Digital MammaPrint test results, Agendia expects to be able to reach a patient population that includes the over 66,000 women in Brazil newly diagnosed with breast cancer in 2020 alone, enabling the possibility for earlier and faster intervention for these women along the entire continuum of care.1

“Incorporating AI into the MammaPrint equation for patients with early-stage breast cancer has the potential to be an unprecedented accelerator for the use of genomic testing and diagnostics in the treatment of this disease, and is potentially transformational for women with breast cancer around the world,” said Mark Straley, Chief Executive Officer of Agendia. “Stratifying breast cancer through AI analysis of a tumor tissue image trained by an astounding amount of our proprietary clinical data has the potential to fundamentally change how breast cancer is treated globally. Enabled by Agendia’s deep understanding and expertise in the functional genomics of breast cancer, we are proud to bring the robust science and clinical benefit that MammaPrint provides together with new digital capabilities, informed by the incredible power of AI, to Brazilian physicians and the women they seek to treat.”

Agendia’s Digital MammaPrint is powered by the cloud-based Paige Platform, a partnership that the two companies announced in November 2020. This is the first product of the collaboration, initially focused on the development of digital tests for early treatment planning where genomic testing has played a crucial role in determining recurrence risk and tumor biology as doctors and their patients make decisions about the path ahead.

“Introducing Digital MammaPrint to physicians and their patients in Brazil marks an important step in increasing access to quality, AI-enabled diagnostic tests,” said David Klimstra, M.D., Founder and Chief Medical Officer at Paige. “We are excited to partner with Agendia to advance our shared goal of transforming pathology data into clear and actionable clinical insights for better patient outcomes.”

On a global scale, access to insights from Digital MammaPrint opens diagnostic care options for women diagnosed with breast cancer worldwide who don’t have access to genomic testing or esoteric lab infrastructure.

“For patients with breast cancer throughout the world who do not live in a location with direct access to genomic testing of their cancer, the ability to obtain such information from a slide image could be revolutionary. The introduction of a digital, AI-informed platform to allow interpretation of the genomic profile of their specific tumor can provide great clinical value and carries the added benefit of preserving valuable tumor tissue for further use in the future. We are using an innovative platform and doing revolutionary work with it,” said William Audeh, M.D., Chief Medical Officer at Agendia. “The ultimate goal is for patients to have access to vital information about their cancer, and this tool has the ability to provide them with that information faster, through digital technology. We believe that the sooner we can get MammaPrint insights into physicians’ hands in their decision-making process, the better it is for their patients.”

Agendia’s MammaPrint is a 70-gene prognostic test that stratifies a specific patient’s recurrence risk and provides a prognostic marker to help inform that risk along with other clinicopathologic factors. MammaPrint informs decisions about pre-operative systemic therapy, adjuvant chemotherapy, and adjuvant endocrine therapy, and the digital capabilities of the test are expected to give physicians and their patients clear and actionable information at these and other critical decision points throughout the cancer care continuum.

About Agendia

Agendia is a mission-driven, commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.

MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan.

For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.

1 Silva, J et.al. 25 Jan. 2021. Breast Cancer Mortality in Young Women in Brazil. Front. Oncol. 10:569933. Doi: 10.3389/fonc.2020.569933.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Media:
Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com

For Agendia Investors:
Mike Cavanaugh
Westwicke/ICR Healthcare IR
Tel: 617.877.9641
Mike.Cavanaugh@westwicke.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enviva Announces Public Offering of Common Stock20.1.2022 00:38:00 EET | Press release

Enviva Inc. (NYSE: EVA) (“Enviva,” “we,” “us,” or “our”) today announced that it has commenced an underwritten public offering (the “Offering”) of 4,300,000 common shares. Enviva expects to grant the underwriters an option to purchase up to an additional 645,000 common shares from Enviva at the issue price of the Offering. Enviva intends to use the net proceeds of the Offering for general corporate purposes, including pre-funding a portion of its capital expenditures related to ongoing development projects, and the temporary repayment of debt. Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Barclays Capital Inc., BMO Capital Markets Corp., HSBC Securities (USA) Inc., RBC Capital Markets, LLC, and Truist Securities are acting as joint book-running managers for the Offering. Loop Capital Markets LLC, Raymond James & Associates, Inc., and USCA Securities LLC are acting as co-managers for the Offering. The Offering is being made pursuant to an effective

Enviva Announces MOU With U.S. Customer, Provides Updates to Business and Sales Pipeline, and Accelerates Capacity Expansions20.1.2022 00:33:00 EET | Press release

Enviva Inc. (NYSE: EVA) (“Enviva,” “we,” “us,” or “our”) today provided a business update announcing a memorandum of understanding (“MOU”) with Enviva’s first U.S.-based customer, and detailing plans to significantly accelerate its capital expansion timeline due to recent commercial momentum with power and heat generators and with industrials in hard-to-abate sectors. The business update also included preliminary 2021 financial results. Highlights: Announced plans to accelerate doubling of production capacity over the next five years, including bringing forward plans for a third plant in the Pascagoula, Mississippi cluster as well as additional plants around Savannah, Georgia and in the mid-Atlantic regions, with capability to build and commission two plants per year, up from one per year Signed MOU with Enviva’s first U.S.-based customer, to develop a supply chain strategy to support the customer’s biofuel refining facilities in the Southeast U.S. and potentially California Announced

DXC Technology Expands Global Partnership with ServiceNow to Accelerate Enterprise Service Management and Operational Transformation, Underpinned by DXC Platform X™20.1.2022 00:00:00 EET | Press release

DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services company, announced the formation of a new global DXC ServiceNow Strategic Business Group to deliver market-leading, cost-efficient, resilient technology services that transform enterprise service operations, built on DXC Platform X TM. DXC has named ServiceNow the preferred workflow partner for DXC Platform X, a data-driven, intelligent automation platform that helps detect, prevent and address issues before they happen with resilient, self-healing IT estates. NelsonHall has named DXC Platform X as a “Leader in Cognitive & Self-Healing IT Infrastructure Management,” reflecting DXC’s ability to deliver immediate benefits through automation while meeting customer requirements for their future operating models. “For our customers, it’s about modernizing and automating their IT estates to achieve a state of ‘silent operations,’ saving time, money and letting customers focus on what’s most important --- running the

Dole Affiliate Receives Social Responsibility in Action Award in Costa Rica19.1.2022 20:57:00 EET | Press release

The American-Costa Rican Chamber of Commerce (AmCham) recognized Dole through its daughter company, Standard Fruit Company de Costa Rica S.A., with the Social Responsibility in Action Award in the Employees Category for their project "De la Mano con Dole" — which loosely translates to "Hand-in-Hand with Dole". This year marks the 25th anniversary of the award which was given December 8, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220119005875/en/ From left: Sandra Lima, Dole Corporate Social Responsibility Senior Manager; Steve Aronson, Horizonte Positivo Board Member; Ana Cristina Obregón, Dole Logistics & Planning Senior Director; Renato Acuña, President of Dole Fresh Fruit Latin America; Gisela Sánchez, AmCham Board President; and Marco Tulio Escobedo, Dole Human Resources Director (Photo: Business Wire) The Hand-in-Hand with Dole project is an initiative that works towards positively impacting the social develop

Q4 Inc. Announces Appointment of Julie Silcock, Investment Banking Veteran, to Board of Directors19.1.2022 20:48:00 EET | Press release

Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), a leading capital markets communications platform, today announced the appointment of Julie Silcock, currently a Senior Advisor at CDX Advisors, bringing 35 years of Capital Markets and M&A experience, to Q4’s Board of Directors, effective immediately. As a Senior Advisor at CDX Advisors, a tech-enabled investment bank, Ms. Silcock is involved in strategic advisory M&A and capital raising activities primarily for growth-oriented companies in the Southwest. Ms. Silcock previously served as Co-Head of Southwest Investment Banking at Houlihan Lokey and, prior to that, founded and acted as Head of Southwest Investment Banking at Citigroup. Ms. Silcock earned her M.B.A. from Stanford Graduate School of Business and holds a B.A. degree from Princeton University. She currently also serves on the boards of MoneyGram International, Overseas Shipholding Group, Inc., a crude oil and petroleum shipping company, JC Skincare, a privately held beauty compa

Alation Launches “Data Radicals” Podcast with Revolutionary Insights Transforming the Way We Use Data19.1.2022 17:00:00 EET | Press release

Alation Inc., the leader in enterprise data intelligence solutions, today announced the debut of its podcast, “Data Radicals.” Hosted by Satyen Sangani, CEO and co-founder of Alation, “Data Radicals” is a show for business, data, and technology enthusiasts who seek to enable individuals and organizations to use data in powerful ways. The podcast kicks off today, with the first 5 episodes available online, as well as Apple Podcasts, Spotify, and anywhere podcasts are available. “Data Radicals” is for anyone interested in how data, science, and technology can help solve the world’s most pressing problems. Episodes explore how data leaders and academics are driving data culture and the role they play in changing how people think and work. The podcast leaves listeners with an understanding of how to facilitate data-driven decision-making and data literacy at all levels of an organization. “The launch of ‘Data Radicals’ gives business leaders, entrepreneurs, and those of us passionate about

Protegrity Partners With Google Cloud to Support BigQuery Remote Functions19.1.2022 17:00:00 EET | Press release

Protegrity, a global leader in data security, today announced it has partnered with Google Cloud to support the upcoming release of BigQuery remote functions. First announced at Google Cloud Next ‘21 in October, BigQuery remote functions offer Google Cloud customers the ability to extend BigQuery with their own external code. With support for remote functions, Protegrity adds an additional layer of data protection, while enabling customers to deliver faster, more robust analysis through Google Cloud BigQuery. Protegrity’s partnership with Google Cloud lays a strong foundation to deliver de-identified data sets across many Google Cloud services. In addition to its support for Google Cloud remote functions, Protegrity also announced the availability of the Cloud API for Google Cloud, a serverless API that can be used to integrate data protection into cloud services and ETL workflows, as well as the Snowflake Protector on Google Cloud. “Through our partnership with Google Cloud, one of th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom